The Signia Pure C&G IX is a premium prescription behind-the-ear hearing aid released in 2023, priced at $4,398. In HearAdvisor's lab testing, it achieved a SoundScore of 4.00/5 and a B grade, placing it in the middle of the prescription hearing aid category.
This device demonstrates solid performance in speech understanding, scoring above the category average in both quiet and noisy environments. Own-voice comfort also tested above average, suggesting good occlusion management for wearers who are sensitive to hearing their own voice. Feedback handling was excellent, achieving a perfect 5.00/5 score in both fit conditions.
However, at this premium price point, the Pure C&G IX faces stiff competition. Several devices in the same price range—including the Oticon Intent (4.70), Phonak Sphere Infinio (4.64), and notably Signia's own Active Pro IX (4.63)—achieved higher overall scores in our testing. Music streaming quality measured slightly below category average, which may be a consideration for users who frequently stream audio content.
The Pure C&G IX is best suited for users who prioritize speech clarity and feedback-free performance, particularly those already comfortable with the Signia ecosystem. Prospective buyers should consider whether the higher-scoring alternatives in this price bracket might better meet their needs, especially if music streaming is a priority.
